Table: Solasia Pharma -9-MTH group results (IFRS)

Solasia Pharma KK

14/11/2017 06:30

Nov 14 (Reuters)-  
              Solasia Pharma K. K.  
              CONSOLIDATED FINANCIAL HIGHLIGHTS  
     (in billions of yen unless specified)  
                   9 months ended      9 months ended        Year to   
                  Sep 30, 2017        Sep 30, 2016      Dec 31, 2017   
                     LATEST             YEAR-AGO           COMPANY     
                     RESULTS             RESULT           FORECAST     
  Sales              409 mln             201 mln           423 mln     
                  (+103.4 pct)                           (-15.6 pct)   
  Operating       loss 424 mln        loss 455 mln        loss 1.79    
  Pretax          loss 430 mln        loss 470 mln        loss 1.79    
  Net             loss 411 mln        loss 458 mln        loss 1.80    
  EPS Basic       loss 5.11 yen      loss 17.46 yen    loss 23.36 yen  
  EPS Diluted     loss 5.11 yen      loss 17.46 yen                    
  Ann Div                                  NIL               NIL       
  -Q2 Div              NIL                 NIL                         
  -Q4 Div                                  NIL               NIL       
  
  NOTE - Solasia Pharma K. K..  
  (Figures are reported based on international accounting rules (IFRS).)  
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half  
  dividend and Q4 to the second-half dividend announced before a new corporate law in  
  2006 allowed companies to pay and report dividends on a quarterly basis. 
  *Net - represents Net profit attributable to owners of the parent company.  
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T  
  ((Tokyo Headline News Desk +813 6441 1812))